[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.142.219. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editor's Correspondence
Oct 10, 2011

Do β-Blockers Slow Down Melanoma Progression?

Author Affiliations

Author Affiliation: Genetic Epidemiology Unit, King's College London, St Thomas' Hospital, London, England.

Arch Intern Med. 2011;171(18):1686-1687. doi:10.1001/archinternmed.2011.483

De Giorgi et al1 reported that use of β-blockers is associated with a reduced risk of melanoma progression. This observation is important because in recent years various novel roles of β-blockers have been introduced. A great example is the successful use of the nonselective β-blocker propranolol, which revolutionized the treatment of infantile hemangioma. Thus, there is a need to further explore the potential therapeutic role of β-blockers in melanoma.

First Page Preview View Large
First page PDF preview
First page PDF preview
×